Literature DB >> 32917263

Reliability of biomarkers of sepsis during extracorporeal therapies: the clinician needs to know what is eliminated and what is not.

Patrick M Honore1, Sebastien Redant2, David De Bels2.   

Abstract

Entities:  

Keywords:  CRRT; Endocan; Heparin binding protein; MR-pro-ADM; Osteopontin; Pentraxin-3; Presepsin; Procalcitonin; Removal of biomarkers

Mesh:

Substances:

Year:  2020        PMID: 32917263      PMCID: PMC7483498          DOI: 10.1186/s13054-020-03277-8

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.

Background

The evolution of renal replacement therapy (RRT) techniques, and the increasing number of critically ill patients receiving extracorporeal therapies, has presented clinicians with a significant problem: if biomarkers are removed by RRT, can they still be considered reliable in their role of guiding diagnosis and treatment? The most commonly used RRT techniques in intensive care units (ICUs) can be classified into three categories: continuous renal replacement therapy (CRRT), intermittent hemodialysis (IHD), and hybrid techniques such as those performed with sorbent devices and plasma exchange (PE). These techniques remove substances from the plasma via convection, adsorption, or a combination of the two. Various factors determine the degree of removal, including molecular weight (MW) and charge, and the type of membrane and RRT technique used. IHD has a cut-off of 5 kDa in most cases and the risk of eliminating biomarkers is small. For CRRT, the cut-off value of the membranes is about 35 kDa, and as a result, filtration of a significant number of biomarkers may occur. New highly adsorptive membranes (HAMs), such as the acrylonitrile 69-surface treated (AN69-ST), are being used more frequently in ICUs [1]. This means that biomarkers with a MW above 35 kDa, while not removed by convection, may potentially be removed in a significant quantity by adsorption. With hybrid devices like CytoSorb, removal of hydrophobic substances with a MW up to 55 kDa occurs via selective binding [2]. PE has a cut-off of 1000 kDa and removes not only biomarkers but also a range of other substances including clotting factors and immunoglobulins. Clearance of a substance cannot always be predicted from MW and RRT membrane characteristics alone, highlighting the need for further studies to determine biomarker levels pre- and post-device for different CRRT techniques. For example, the relatively small MW (25 kDa) of high mobility group protein B1 (HMGB1), a damage-associated molecular pattern (DAMP) and marker of outcome, in theory does not prohibit its removal by convection. However, HMGB-1 is not eliminated by convection and is only effectively cleared through adsorption by HAMs like AN69-ST [3]. This occurs because it has a flat shape, and this prevents its passage through a CRRT membrane, despite its small MW. The degree of biomarkers removal by RRT, with the consequent effect on their serum levels, is essential information for clinicians (Fig. 1).
Fig. 1

Biomarker molecular weight and removal by CRRT membranes

Biomarker molecular weight and removal by CRRT membranes

Biomarkers eliminated by CRRT and sorbents

C-reactive protein (CRP) is the most commonly used biomarker of inflammation. While often thought of as a pentamer with a MW of 125 kDa, CRP is predominantly present as a monomer (mCRP, MW 22–25 kDa) in the blood of septic patients and as such is removed by all forms of CRRT. Substantial amounts can also be eliminated via adsorption, by both conventional CRRT membranes and the CytoSorb device [4]. Procalcitonin (PCT), a biomarker used to detect (and exclude) the presence of infection and to monitor response to treatment, has a MW of 13.5 kDa and has been detected in the ultrafiltrate of patients undergoing CRRT [5]. Most of the PCT is eliminated by convection, but adsorption also contributes to elimination during the first hours of treatment [5]. B-type natriuretic peptide (BNP) and N-terminal pro-BNP (NT-proBNP), biomarkers of cardiac dysfunction and outcome in sepsis, are also highly likely to be easily cleared by CRRT given their low MWs (3.5 kDa for BNP and 8.5 kDa for NT-proBNP) [6]. Mid-regional pro-adrenomedullin (MR-pro-ADM), a biomarker of sepsis severity and response to treatment, has a MW between 4 and 5.5 kDa, and its plasma concentration has been shown to decrease by 45–65% if a high-flux membrane is used [7]. Recently, presepsin has also been identified as a diagnostic biomarker of sepsis [8]. It has a MW of 13 kDa, which theoretically means that it could be subject to significant convective elimination. Given that RRT artificially decreases creatinine levels, a patient under RRT should be considered as having the full acute kidney injury in any score.

Biomarkers not eliminated by CRRT or sorbents but needing further investigation

Endocan is a diagnostic and prognostic biomarker for sepsis and acute respiratory distress syndrome [9]. CRRT with a membrane cut-off of 35 kDa is unlikely to remove endocan (MW 40 kDa), but removal may possibly occur by adsorption when HAMs are used [10]. Pentraxin 3 (PTX3), a marker of sepsis severity and a diagnostic marker for ventilator-associated pneumonia [11], has a MW of 35 kDa and thus, in theory, can be removed by CRRT. However, a recent study demonstrated little or no clearance or absorption by the filter during CVVH [12]. Heparin binding protein (HBP), a predictor of sepsis-induced organ dysfunction [13], has a MW of 37 kDa and as such should not be removed by convection. HBP has been detected in the effluent of patients undergoing CRRT, without a consistent decrease in plasma levels [14]. Studies are needed to investigate whether adsorption is possible. Osteopontin (OPN) is a predictor of outcome in critically ill patients [15]. A highly negatively charged protein with a MW of 32 kDa, osteopontin can theoretically be removed by CRRT, but at this time evidence is lacking. Table 1 summarizes all biomarkers described in this review with their MW, ability to be removed by convection and/or adsorption, and whether a study focusing on removal via RRT has been performed.
Table 1

Biomarker molecular weight, potential removal by CRRT or sorbents, and summary of the available studies and the studies that need to be realized of levels in the context of RRT

BiomarkerMolecular weight (kDa)Elimination by CRRTElimination by sorbentsExisting studiesStudies needed
mCRP20–25++++
PCT14.5++++
BNP3.5++++
NT-ProBNP8.5++++
HMGB-125+ (adsorption only)++
OPN++
Endocan40++
MR-pro-ADM4–5.5++
PTX335+++
Presepsin13++++
HBP37++

kDa kilodalton, CRRT continuous renal replacement therapy, mCRP monomeric C-reactive protein, PCT procalcitonin, NT-ProBNP N-terminal pro-hormone of brain natriuretic peptide, OPN osteopontin, HMGB-1 high mobility group protein B1, MR-pro-ADM mid-regional pro-adrenomedullin, HBP heparin binding protein

Biomarker molecular weight, potential removal by CRRT or sorbents, and summary of the available studies and the studies that need to be realized of levels in the context of RRT kDa kilodalton, CRRT continuous renal replacement therapy, mCRP monomeric C-reactive protein, PCT procalcitonin, NT-ProBNP N-terminal pro-hormone of brain natriuretic peptide, OPN osteopontin, HMGB-1 high mobility group protein B1, MR-pro-ADM mid-regional pro-adrenomedullin, HBP heparin binding protein

Conclusions

It is likely that many sepsis biomarkers may be removed by convection, and therefore, their reliability as markers in patients undergoing CRRT is under question. Furthermore, the increasing use of HAMs makes the removal of many biomarkers even more likely. It is possible that some biomarkers may still have utility in the role of guiding diagnosis and treatment of critically ill patients on CRRT; however, further studies exploring biomarker elimination by CRRT are needed to confirm this. The development of new reference ranges for biomarkers in the setting of RRT would also be an interesting avenue of study. Beyond their utility as biomarkers, there are still many other questions to answer, such as whether removal of these, and other, substances by CRRT may result in benefit or harm.
  15 in total

1.  In vitro evaluation of high mobility group box 1 protein removal with various membranes for continuous hemofiltration.

Authors:  Miho Yumoto; Osamu Nishida; Kazuhiro Moriyama; Yasuyo Shimomura; Tomoyuki Nakamura; Naohide Kuriyama; Yoshitaka Hara; Shingo Yamada
Journal:  Ther Apher Dial       Date:  2011-08       Impact factor: 1.762

Review 2.  What Have We Learned about the Use of Cytosorb Adsorption Columns?

Authors:  Ghada Ankawi; Yun Xie; Bo Yang; Yuanyuan Xie; Pan Xie; Claudio Ronco
Journal:  Blood Purif       Date:  2019-04-30       Impact factor: 2.614

Review 3.  Membranes and Sorbents.

Authors:  William R Clark; Dayong Gao; Anna Lorenzin; Claudio Ronco
Journal:  Contrib Nephrol       Date:  2018-03-29       Impact factor: 1.580

Review 4.  Pentraxin 3: an immune modulator of infection and useful marker for disease severity assessment in sepsis.

Authors:  Patrick Ketter; Jieh-Juen Yu; Andrew P Cap; Thomas Forsthuber; Bernard Arulanandam
Journal:  Expert Rev Clin Immunol       Date:  2016-03-31       Impact factor: 4.473

Review 5.  Heparin-binding protein: a key player in the pathophysiology of organ dysfunction in sepsis.

Authors:  J Fisher; A Linder
Journal:  J Intern Med       Date:  2017-03-28       Impact factor: 8.989

6.  Elimination of the cardiac natriuretic peptides B-type natriuretic peptide (BNP) and N-terminal proBNP by hemodialysis.

Authors:  Hans Günther Wahl; Stephanie Graf; Harald Renz; Winfried Fassbinder
Journal:  Clin Chem       Date:  2004-06       Impact factor: 8.327

7.  Changes of Serum Procalcitonin (PCT), C-Reactive Protein (CRP), Interleukin-17 (IL-17), Interleukin-6 (IL-6), High Mobility Group Protein-B1 (HMGB1) and D-Dimer in Patients with Severe Acute Pancreatitis Treated with Continuous Renal Replacement Therapy (CRRT) and Its Clinical Significance.

Authors:  Ning Gao; Chengjun Yan; Guochang Zhang
Journal:  Med Sci Monit       Date:  2018-08-23

8.  Endocan is a reliable biomarker during continuous renal replacement therapy.

Authors:  Maxence Hureau; Alexandre Gaudet; Nathalie De Freitas Caires; Erika Parmentier; Julien Poissy; Thibault Duburcq; Philippe Lassalle; Daniel Mathieu
Journal:  Crit Care       Date:  2019-09-03       Impact factor: 9.097

9.  An evaluation of clinical inflammatory and coagulation markers in patients with sepsis: a pilot study.

Authors:  Emi Fujii; Kazunori Fujino; Yutaka Eguchi
Journal:  Acute Med Surg       Date:  2019-03-01

10.  Renal clearance of heparin-binding protein and elimination during renal replacement therapy: Studies in ICU patients and healthy volunteers.

Authors:  Line Samuelsson; Jonas Tydén; Heiko Herwald; Magnus Hultin; Jakob Walldén; Ingrid Steinvall; Folke Sjöberg; Joakim Johansson
Journal:  PLoS One       Date:  2019-08-29       Impact factor: 3.240

View more
  7 in total

1.  The authors reply.

Authors:  Sikandar H Khan; Anthony J Perkins; Sujuan Gao; Babar A Khan
Journal:  Crit Care Med       Date:  2021-07-01       Impact factor: 9.296

Review 2.  New Decade, Old Debate: Blocking the Cytokine Pathways in Infection-Induced Cytokine Cascade.

Authors:  Mahrukh S Rizvi; Alice Gallo De Moraes
Journal:  Crit Care Explor       Date:  2021-03-23

3.  High levels of plasma biomarkers at 24 h were found to be strong predictors of 90-day mortality: beware of some potential confounders!

Authors:  Patrick M Honore; Sebastien Redant; Thierry Preseau; Keitiane Kaefer; Leonel Barreto Gutierrez; Rachid Attou; Andrea Gallerani; David De Bels
Journal:  Ann Intensive Care       Date:  2021-03-15       Impact factor: 6.925

4.  Effects of intermittent hemodialysis on plasmatic levels of endocan.

Authors:  Maxence Hureau; Julien Poissy; Daniel Mathieu; Sylvain Dubucquoi; Alexandre Gaudet
Journal:  Crit Care       Date:  2021-11-29       Impact factor: 9.097

Review 5.  Biomarkers Predicting Tissue Pharmacokinetics of Antimicrobials in Sepsis: A Review.

Authors:  Maria Sanz Codina; Markus Zeitlinger
Journal:  Clin Pharmacokinet       Date:  2022-02-25       Impact factor: 5.577

6.  Success rate of naso-jejunal tube placement influenced by CRRT: possible removal of metoclopramide.

Authors:  Patrick M Honore; Sebastien Redant; Thierry Preseau; Sofie Moorthamers; Keitiane Kaefer; Leonel Barreto Gutierrez; Rachid Attou; Andrea Gallerani; David De Bels
Journal:  Crit Care       Date:  2021-06-30       Impact factor: 9.097

7.  MR-proADM has a good ability to predict 28-day mortality in critically ill patients with SARS-CoV-2 pneumonia: Beware of some potential confounders!

Authors:  Patrick M Honore; Sebastien Redant; Sofie Moorthamers; Thierry Preseau; Keitiane Kaefer; Leonel Barreto Gutierrez; Rachid Attou; Andrea Gallerani; David De Bels
Journal:  J Crit Care       Date:  2021-10-22       Impact factor: 3.425

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.